Miniature colon spectral scanner that gives real time automatic alerts for patho...
Miniature colon spectral scanner that gives real time automatic alerts for pathological findings.
The lifetime risk of developing colorectal cancer (CRC) is about 1 in 22 for men and 1 in 24 for women and this risk increases with age. CRC represents 22% of the total cancer-related costs. It usually begins as a non-cancerou...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto LEAD
Duración del proyecto: 4 meses
Fecha Inicio: 2018-05-09
Fecha Fin: 2018-09-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The lifetime risk of developing colorectal cancer (CRC) is about 1 in 22 for men and 1 in 24 for women and this risk increases with age. CRC represents 22% of the total cancer-related costs. It usually begins as a non-cancerous growth called a polyp that develops on the inner lining of the colon or rectum and grows slowly over a period of 10 to 20 years. Research has confirmed that the single best prevention for colon cancer is the early detection and removal of all colon polyps. When colorectal cancer is found at an early stage, the 5-year relative survival rate is about 90% which makes it suitable for screening programs. LEAD (LEsion Auto-Detector) is a cost-effective (€50), disposable miniature colon spectral scanner that drastically improves polyp detection (99%). It features a 360° light emitting ring that scans the colon, automatically processes different wavelengths from the reflected spectral data and provides real-time alerts based on accurate pathological tissue analysis. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of LEAD in Europe before a global expansion. Following this, we are aiming to secure vital funding for an important clinical study to prove the efficacy of our revolutionary colonoscope add-on.